Domperidone in Secondary Progressive Multiple Sclerosis (SPMS)

• Status: Completed
• Trial end date: 2020-01-03
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this clinical trial is to determine if Domperidone in a dose of 40 mg daily can prevent worsening of walking ability in people secondary progressive MS. The number of participants in this study will be 62. A maximum of 75 people with secondary progressive MS will be included. Each patient will be followed for 12 months from inclusion. Domperidone is a medication which has been shown to increase levels of the hormone prolactin. The best understood function of prolactin is the stimulation of milk production in women after delivery. However, the increase in prolactin levels seen in patients treated with standard doses of Domperidone (in doses of up to 80mg per day) usually does not lead to clinical symptoms. Prolactin has been shown to improve myelin repair in mice. Domperidone therefore may also improve myelin repair in people with MS. Domperidone is currently approved in Canada to treat slow moving bowels and nausea, for instance in patients with Parkinson's Disease or Diabetes Mellitus, where too slowly moving bowels can cause constipation. Domperidone is available as a tablet that is usually taken four times per day. Doses up to 80mg per day may be used but we estimate that a dose of only 40mg daily will be needed to stimulate myelin repair. Domperidone is usually well tolerated.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Calgary
• Collaborator: Alberta Innovates Health Solutions
• Treatments: Domperidone

Criteria

Inclusion Criteria:

• written informed consent obtained

• with Multiple Sclerosis, and with secondary progressive disease course

• screening Expanded Disability Status Scale (EDSS) score between 4.0 and 6.5 inclusive

• screening timed 25 foot walk (average of two trials) lof 9 seconds or more

Exclusion Criteria:

• Long QT interval, defined as corrected QT interval of more than 470 msec in men and more than 450 msec in women on baseline ECG

• Patients with known long-QT syndrome

• Patients with known ventricular arrhythmia

• Patients with a known electrolyte disturbance

• Patients undergoing treatment with drugs that increase the QTc interval

• Patients undergoing treatment with drugs that inhibit CYP3A4, in particular:

Ketoconazole, Fluconazole, Erythromycin, Clarithromycin, Ritonavir

• Patients with a history of breast cancer or carcinoma in situ

• Patients with known renal insufficiency

• Patients with known allergy or other intolerability to domperidone

• Patients currently using Fampridine or 4-aminopyridine

• Patients planning to start Fampridine or 4-aminopyridine during the study period

• Patients planning to start Baclofen or Tizanidine during the duration of the study

• Patients planning to increase or decrease their dose of Baclofen or Tizanidine during the study period

• Patients planning to receive treatment with Botulinum toxin in the leg muscles during the duration of the study

• Patients with a significiant hepatic impairment

• Patients with a prolactinoma

• Patients in whom gastrointestinal stimulation could be dangerous

• Patients using MAO inhibitors

• Patients with a history of breast cancer

• Pregnant or breast-feeding women